BEAM · Beam Therapeutics Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on BEAM. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About BEAM · Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Live Quote
BUY (score +7) · 12-1 mom 61.3% · RSI 56.6 · above_both · -6.6% from high
Targets blend Wall Street consensus (15 analysts: low $26.00 / mean $51.07 / high $80.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage crashed before producing an artifact (e.g. LM Studio timeout, malformed JSON, network error). The cooldown will hold this off the queue for ~1h before retry.
Beam Therapeutics is a pre-commercial base-editing biotech with two high-value catalysts approaching: (1) a potential sickle cell BLA filing by end-2026 and (2) a pivotal expansion cohort for BEAM-302 in alpha-1 antitrypsin deficiency (AATD) beginning H2 2026 after strong Phase 1/2 dose-selection data presented at ATS May 2026. The stock has surged ~23% YTD on the back of positive clinical updates, reaching $36.44 intraday high before today's -10.5% pullback to $29.40. Vanguard disclosed a ~5% stake in April 2026 and multiple insider open-market purchases clustered around late January (post-Q4 results) and March-April suggest smart-money conviction at higher levels than current price. The company has ~3 years of cash runway, elevated IV (75-90%) creating income structure opportunity, and the analyst consensus target of $51 implies 74% upside from here. SEC rate-limiting prevented direct reading of 10-K/10-Q text, but cross-referencing news + fundamentals yields a coherent picture: pre-commercial gene editor with near-term regulatory catalyst — fully priced on pure hope OR meaningfully undervalued given where insiders are buying? The answer determines whether this is 'promising' or 'range_bound_or_income'.